Long-term effectiveness and safety of Canakinumab in patients with TRAPS: analysis of the RELIANCE non-interventional study
Introduction: This is an interim analysis of the long-term effectiveness and safety of canakinumab in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) cohort of the RELIANCE non-interventional study. Methods: From June 2018, the RELIANCE non-interventional study enrolled paedi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2026
|
| In: |
Rheumatology and therapy
Year: 2026, Jahrgang: 13, Heft: 1, Pages: 135-155 |
| ISSN: | 2198-6584 |
| DOI: | 10.1007/s40744-025-00809-y |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s40744-025-00809-y
|
| Verfasserangaben: | Norbert Blank, Catharina Schuetz, Markus Hufnagel, Gerd Horneff, Michael Borte, Tilmann Kallinich, Prasad T. Oommen, Ales Janda, Joerg Henes, Julia Weber-Arden, Michael Stock, Jasmin B. Kuemmerle-Deschner |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1950598705 | ||
| 003 | DE-627 | ||
| 005 | 20260129121527.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260129s2026 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40744-025-00809-y |2 doi | |
| 035 | |a (DE-627)1950598705 | ||
| 035 | |a (DE-599)KXP1950598705 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Blank, Norbert |d 1964- |e VerfasserIn |0 (DE-588)115586032 |0 (DE-627)691431507 |0 (DE-576)289963508 |4 aut | |
| 245 | 1 | 0 | |a Long-term effectiveness and safety of Canakinumab in patients with TRAPS |b analysis of the RELIANCE non-interventional study |c Norbert Blank, Catharina Schuetz, Markus Hufnagel, Gerd Horneff, Michael Borte, Tilmann Kallinich, Prasad T. Oommen, Ales Janda, Joerg Henes, Julia Weber-Arden, Michael Stock, Jasmin B. Kuemmerle-Deschner |
| 264 | 1 | |c 2026 | |
| 300 | |b Illustrationen | ||
| 300 | |a 21 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 26. November 2025 | ||
| 500 | |a Gesehen am 29.01.2026 | ||
| 520 | |a Introduction: This is an interim analysis of the long-term effectiveness and safety of canakinumab in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) cohort of the RELIANCE non-interventional study. Methods: From June 2018, the RELIANCE non-interventional study enrolled paediatric (aged ≥ 2 – < 18 years) and adult patients (aged ≥ 18 years) with TRAPS who were receiving canakinumab as part of their routine medical care. Physician- and patient-reported measures of disease activity, dosing patterns and safety were evaluated at baseline and every 6 months until the end-of-study visit.Results: A total of 21 patients with TRAPS were enrolled by the analysis cut-off date of December 2022, of which 61.9% (13/21) were paediatric patients (< 18 years) and 66.7% (14/21) were female. All patients were pre-treated with canakinumab prior to enrolment (median duration of canakinumab treatment prior to study inclusion: 1.2 years). Disease activity, evaluated by physician-reported (physician’s global assessment, disease remission, C-reactive protein, serum amyloid A) and patient-reported (disease activity, fatigue, impact on social life, autoinflammatory disease activity index diary) measures, was generally well controlled throughout the study. At baseline, the majority of patients (71.4%) were receiving the recommended starting dose (SD) of canakinumab, with a more even distribution between the < SD, SD, and > SD dosing schedules observed from month 6. No serious adverse drug reactions were reported. Patients continued to receive vaccinations during long-term treatment with canakinumab. In total, 85.7% (18/21) of patients met the Eurofever/PRINTO classification criteria for TRAPS, 42.9% (9/21) with the presence of a confirmative TNFRSF1A genotype and 42.9% (9/21) without. In total, 14.3% (3/21) of patients did not meet the classification criteria.Conclusions: Data from this interim analysis support the long-term effectiveness and safety of canakinumab for the treatment of TRAPS. | ||
| 650 | 4 | |a Autoinflammatory diseases | |
| 650 | 4 | |a Canakinumab | |
| 650 | 4 | |a Fever syndromes | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a TNFRSF1A | |
| 650 | 4 | |a Tumor necrosis factor receptor-associated periodic syndrome | |
| 700 | 1 | |a Schuetz, Catharina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hufnagel, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Horneff, Gerd |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borte, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kallinich, Tilmann |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oommen, Prasad T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Janda, Ales |e VerfasserIn |4 aut | |
| 700 | 1 | |a Henes, Joerg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weber-Arden, Julia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stock, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuemmerle-Deschner, Jasmin B. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology and therapy |d [Erscheinungsort nicht ermittelbar] : Springer Healthcare, 2014 |g 13(2026), 1, Seite 135-155 |h Online-Ressource |w (DE-627)795566832 |w (DE-600)2783278-8 |w (DE-576)413960684 |x 2198-6584 |7 nnas |a Long-term effectiveness and safety of Canakinumab in patients with TRAPS analysis of the RELIANCE non-interventional study |
| 773 | 1 | 8 | |g volume:13 |g year:2026 |g number:1 |g pages:135-155 |g extent:21 |a Long-term effectiveness and safety of Canakinumab in patients with TRAPS analysis of the RELIANCE non-interventional study |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s40744-025-00809-y |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260129 | ||
| 993 | |a Article | ||
| 994 | |a 2026 | ||
| 998 | |g 115586032 |a Blank, Norbert |m 115586032:Blank, Norbert |d 910000 |d 910100 |d 50000 |e 910000PB115586032 |e 910100PB115586032 |e 50000PB115586032 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1950598705 |e 4864512035 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Blank","display":"Blank, Norbert","role":"aut","given":"Norbert"},{"display":"Schuetz, Catharina","role":"aut","given":"Catharina","family":"Schuetz"},{"family":"Hufnagel","display":"Hufnagel, Markus","given":"Markus","role":"aut"},{"given":"Gerd","role":"aut","display":"Horneff, Gerd","family":"Horneff"},{"given":"Michael","role":"aut","display":"Borte, Michael","family":"Borte"},{"given":"Tilmann","role":"aut","display":"Kallinich, Tilmann","family":"Kallinich"},{"role":"aut","given":"Prasad T.","display":"Oommen, Prasad T.","family":"Oommen"},{"family":"Janda","display":"Janda, Ales","role":"aut","given":"Ales"},{"family":"Henes","given":"Joerg","role":"aut","display":"Henes, Joerg"},{"family":"Weber-Arden","given":"Julia","role":"aut","display":"Weber-Arden, Julia"},{"family":"Stock","given":"Michael","role":"aut","display":"Stock, Michael"},{"display":"Kuemmerle-Deschner, Jasmin B.","given":"Jasmin B.","role":"aut","family":"Kuemmerle-Deschner"}],"name":{"displayForm":["Norbert Blank, Catharina Schuetz, Markus Hufnagel, Gerd Horneff, Michael Borte, Tilmann Kallinich, Prasad T. Oommen, Ales Janda, Joerg Henes, Julia Weber-Arden, Michael Stock, Jasmin B. Kuemmerle-Deschner"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"disp":"Long-term effectiveness and safety of Canakinumab in patients with TRAPS analysis of the RELIANCE non-interventional studyRheumatology and therapy","id":{"eki":["795566832"],"zdb":["2783278-8"],"issn":["2198-6584"]},"note":["Gesehen am 14.08.20"],"origin":[{"publisherPlace":"[Erscheinungsort nicht ermittelbar]","publisher":"Springer Healthcare","dateIssuedDisp":"2014-","dateIssuedKey":"2014"}],"recId":"795566832","type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Rheumatology and therapy","title":"Rheumatology and therapy"}],"part":{"issue":"1","extent":"21","pages":"135-155","text":"13(2026), 1, Seite 135-155","year":"2026","volume":"13"},"language":["eng"],"pubHistory":["Nachgewiesen 2014 -"]}],"note":["Online veröffentlicht: 26. November 2025","Gesehen am 29.01.2026"],"physDesc":[{"extent":"21 S.","noteIll":"Illustrationen"}],"id":{"doi":["10.1007/s40744-025-00809-y"],"eki":["1950598705"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1950598705","origin":[{"dateIssuedKey":"2026","dateIssuedDisp":"2026"}],"language":["eng"],"title":[{"title_sort":"Long-term effectiveness and safety of Canakinumab in patients with TRAPS","subtitle":"analysis of the RELIANCE non-interventional study","title":"Long-term effectiveness and safety of Canakinumab in patients with TRAPS"}]} | ||
| SRT | |a BLANKNORBELONGTERMEF2026 | ||